MCID: NRL005
MIFTS: 61

Neurilemmoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neurilemmoma

MalaCards integrated aliases for Neurilemmoma:

Name: Neurilemmoma 12 52 58 43 15 71
Schwannoma 12 52 54 6 17
Benign Schwannoma 52 58 71
Peripheral Fibroblastoma 52 58
Neurilemoma 52 58
Psammomatous Schwannoma 12
Neurolemmoma 52
Schwannomas 15

Characteristics:

Orphanet epidemiological data:

58
benign schwannoma
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3192
MeSH 43 D009442
NCIt 49 C3269
SNOMED-CT 67 189948006
UMLS via Orphanet 72 C0027809 C0854906
Orphanet 58 ORPHA252164
UMLS 71 C0027809 C0854906

Summaries for Neurilemmoma

NIH Rare Diseases : 52 A schwannoma is a tumor of the peripheral nervous system or nerve root. A schwannoma develops from cells called Schwann cells , a type of cell that wraps itself around peripheral nerves and provides protection and support. Schwannomas are almost always benign (not cancerous), but rarely, may become cancerous (a malignant schwannoma ). Symptoms of a schwannoma may be vague and will vary depending on its location and size, but may include a lump or bump that can be seen or felt, pain, muscle weakness, tingling, numbness, hearing problems, and/or facial paralysis. Sometimes schwannomas do not cause any symptoms. Schwannomas usually develop in otherwise healthy people for unknown reasons. In some cases, a schwannoma is caused by a genetic disorder such as neurofibromatosis 2 (NF2), schwannomatosis , or Carney complex . People with these genetic disorders usually have more than one schwannoma. Schwannomas may be diagnosed using imaging studies . A biopsy may confirm the diagnosis. Treatment of benign schwannomas may involve surgery to remove the tumor. Treatment of malignant schwannomas may include both surgery and radiation therapy .

MalaCards based summary : Neurilemmoma, also known as schwannoma, is related to peripheral nerve schwannoma and melanotic neurilemmoma. An important gene associated with Neurilemmoma is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are Neuroscience and Cytoskeletal Signaling. The drugs Anti-Bacterial Agents and Gentamicins have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and tongue, and related phenotypes are abnormal temporal bone morphology and vestibular schwannoma

Wikipedia : 74 A schwannoma is a usually benign nerve sheath tumor composed of Schwann cells, which normally produce... more...

Related Diseases for Neurilemmoma

Diseases related to Neurilemmoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1064)
# Related Disease Score Top Affiliating Genes
1 peripheral nerve schwannoma 34.5 SMARCB1 NF2 NF1
2 melanotic neurilemmoma 34.3 PRKAR1A NF2 CD34
3 adult malignant schwannoma 34.2 NF2 NF1 CD34
4 neurofibromatosis, type ii 34.1 RDX NF2 NF1 MSN EZR
5 malignant triton tumor 33.1 S100B NF1 ENO2
6 cellular schwannoma 33.0 SOX10 S100A1 NF2 NF1 CD34
7 intraneural perineurioma 32.9 S100B S100A1 NF2 MUC1
8 neurilemmomatosis 32.9 SOX10 SMARCB1 PRKAR1A NF2 NF1
9 schwannoma of twelfth cranial nerve 32.9 SMARCB1 NF2 NF1
10 schwannomatosis 1 32.8 SMARCB1 NF2
11 plexiform schwannoma 32.7 SOX10 NF2 NF1 KIT ENO2 CD34
12 acoustic neuroma 32.5 SMARCB1 RDX NGFR NF2 NF1 MSN
13 atypical teratoid rhabdoid tumor 32.4 VIM SMARCB1 S100B S100A1 MUC1 GFAP
14 gastrointestinal stromal tumor 31.7 VIM SMARCB1 S100B S100A1 PDGFRA NF2
15 malignant peripheral nerve sheath tumor 31.7 VIM SOX10 SMARCB1 S100B S100A1 PDGFRA
16 neurofibromatosis 31.5 RDX PDGFRA NF2 NF1
17 spinal meningioma 31.5 SMARCB1 NF2 NF1
18 rare tumor 31.4 NF2 KIT ACTC1
19 mesenchymal cell neoplasm 31.4 PDGFRA KIT CD34
20 hydrocephalus 31.3 VIM SMARCB1 S100B NES GFAP ENO2
21 secretory meningioma 31.2 VIM SMARCB1 NF2 MUC1
22 exophthalmos 31.2 NF1 ENO2 CD34
23 plexiform neurofibroma 31.1 S100B PDGFRA NF2 NF1 KIT
24 monosomy 22 31.1 SMARCB1 NF2
25 obstructive hydrocephalus 31.0 NF2 NF1 GFAP ENO2
26 ganglioneuroma 31.0 S100B GFAP ENO2
27 angiosarcoma 30.9 VIM MUC1 KIT CD34
28 epidural spinal canal neoplasm 30.9 NF2 CD34
29 connective tissue benign neoplasm 30.9 NF1 KIT ENO2 CD34
30 optic nerve sheath meningioma 30.8 SMARCB1 NF2 NF1
31 hemangioma 30.8 MUC1 KIT ENO2 CD34 ACTC1
32 fibroma 30.8 VIM S100A1 NF1 CD34 ACTC1
33 granular cell tumor 30.8 VIM S100B S100A1 GFAP ENO2
34 fasciitis 30.7 VIM GFAP CD34 ACTC1
35 leiomyoma 30.7 VIM S100A1 PDGFRA KIT CD34 ACTC1
36 lipomatosis, multiple 30.7 NF1 KIT CD34
37 cystic teratoma 30.7 KIT GFAP ENO2
38 embryonal sarcoma 30.6 VIM S100B KIT
39 fibrosarcoma 30.6 VIM PDGFRA KIT ACTC1
40 pseudosarcomatous fibromatosis 30.6 VIM CD34 ACTC1
41 neurofibrosarcoma 30.6 S100A1 NF2 NF1 ENO2 CD34
42 benign giant cell tumor 30.6 VIM MUC1 ACTC1
43 pleomorphic adenoma 30.5 VIM S100B S100A1 MUC1 GFAP ACTC1
44 rhabdoid tumor predisposition syndrome 1 30.5 VIM SMARCB1 MUC1 ACTC1
45 glioblastoma multiforme 30.5 PDGFRA NF2 NF1 NES KIT GFAP
46 juvenile pilocytic astrocytoma 30.5 SOX10 S100B NF1 NES GFAP
47 neurofibromatosis, type i 30.5 S100B PDGFRA NF2 NF1 KIT
48 meningioma, radiation-induced 30.5 VIM SMARCB1 S100B RDX NF2 MUC1
49 paraganglioma 30.5 S100B NF1 KIT GFAP ENO2
50 olfactory neuroblastoma 30.5 VIM S100B NGFR ENO2

Graphical network of the top 20 diseases related to Neurilemmoma:



Diseases related to Neurilemmoma

Symptoms & Phenotypes for Neurilemmoma

Human phenotypes related to Neurilemmoma:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal temporal bone morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0009911
2 vestibular schwannoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0009588
3 peripheral schwannoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0009593
4 abnormality of peripheral nervous system electrophysiology 58 31 hallmark (90%) Very frequent (99-80%) HP:0030177
5 scleral schwannoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0100011
6 hearing abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0000364
7 vertigo 58 31 frequent (33%) Frequent (79-30%) HP:0002321
8 facial palsy 58 31 frequent (33%) Frequent (79-30%) HP:0010628
9 allodynia 58 31 frequent (33%) Frequent (79-30%) HP:0012533
10 abnormality of the adrenal glands 58 31 occasional (7.5%) Occasional (29-5%) HP:0000834
11 nasal polyposis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100582
12 abnormality of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0001392
13 intestinal polyposis 58 31 occasional (7.5%) Occasional (29-5%) HP:0200008
14 abnormality of the larynx 58 31 occasional (7.5%) Occasional (29-5%) HP:0001600
15 abnormality of fibula morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002991
16 abnormal parotid gland morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0000197
17 abnormality of the breast 58 31 occasional (7.5%) Occasional (29-5%) HP:0000769
18 abnormal esophagus morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002031
19 acute episodes of neuropathic symptoms 58 31 occasional (7.5%) Occasional (29-5%) HP:0003489
20 abnormality of the twelfth cranial nerve 58 31 occasional (7.5%) Occasional (29-5%) HP:0010826
21 morphological central nervous system abnormality 31 occasional (7.5%) HP:0002011
22 abnormal cranial nerve morphology 58 Very frequent (99-80%)
23 morphological abnormality of the central nervous system 58 Occasional (29-5%)
24 pain 58 Occasional (29-5%)
25 schwannoma 58 Very frequent (99-80%)
26 neurofibrosarcoma 58 Excluded (0%)

GenomeRNAi Phenotypes related to Neurilemmoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.66 PDGFRA
2 Decreased viability GR00221-A-1 9.66 KIT NF1 PDGFRA PRKAR1A SMARCB1
3 Decreased viability GR00221-A-2 9.66 NF1 PRKAR1A SMARCB1
4 Decreased viability GR00221-A-3 9.66 PDGFRA PRKAR1A SMARCB1
5 Decreased viability GR00221-A-4 9.66 NF1 PDGFRA PRKAR1A
6 Decreased viability GR00249-S 9.66 NF1 PDGFRA SMARCB1
7 Decreased viability GR00301-A 9.66 KIT
8 Decreased viability GR00381-A-1 9.66 SMARCB1
9 Decreased viability GR00386-A-1 9.66 NF1
10 Decreased viability GR00402-S-2 9.66 PDGFRA
11 Decreased cell migration GR00055-A-1 9.26 NF2 PRKAR1A VIM
12 Decreased cell migration GR00055-A-3 9.26 RDX

MGI Mouse Phenotypes related to Neurilemmoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 ENO2 GFAP KIT NF1 NF2 NGFR
2 cellular MP:0005384 10.39 ACTC1 CD34 ENO2 GFAP KIT MSN
3 homeostasis/metabolism MP:0005376 10.38 ACTC1 CD34 GFAP KIT MSN NF1
4 growth/size/body region MP:0005378 10.29 ACTC1 ENO2 EZR GFAP KIT NF1
5 cardiovascular system MP:0005385 10.26 ACTC1 GFAP KIT NF1 NGFR PDGFRA
6 hematopoietic system MP:0005397 10.24 CD34 EZR KIT MSN NF1 NGFR
7 immune system MP:0005387 10.23 CD34 EZR GFAP KIT MSN NF1
8 mortality/aging MP:0010768 10.22 ACTC1 EZR GFAP KIT NF1 NF2
9 digestive/alimentary MP:0005381 10.18 EZR GFAP KIT NF1 NGFR PDGFRA
10 integument MP:0010771 10.13 CD34 KIT NF1 NF2 NGFR PDGFRA
11 craniofacial MP:0005382 10.08 ENO2 KIT NF1 NF2 NGFR PDGFRA
12 muscle MP:0005369 10.07 ACTC1 GFAP KIT NF1 NGFR PDGFRA
13 nervous system MP:0003631 10.03 ACTC1 ENO2 GFAP KIT NF1 NF2
14 neoplasm MP:0002006 9.92 CD34 KIT NF1 NF2 PDGFRA PRKAR1A
15 normal MP:0002873 9.9 ACTC1 GFAP KIT MSN NF1 NGFR
16 respiratory system MP:0005388 9.36 ENO2 KIT MSN NF1 NF2 NGFR
17 pigmentation MP:0001186 9.35 KIT NF1 PDGFRA PRKAR1A SOX10

Drugs & Therapeutics for Neurilemmoma

Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4
2 Gentamicins Phase 4
3 Anti-Infective Agents Phase 4
4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
5
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
8 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
9
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
10 Anti-Inflammatory Agents Phase 3
11 Antineoplastic Agents, Hormonal Phase 3
12 Gastrointestinal Agents Phase 3
13 Methylprednisolone Acetate Phase 3
14 Hormones Phase 3
15 Antiemetics Phase 3
16 Neuroprotective Agents Phase 3
17 Hormone Antagonists Phase 3
18 glucocorticoids Phase 3
19 Protective Agents Phase 3
20
Bevacizumab Approved, Investigational Phase 2 216974-75-3
21
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
22
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
23
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
24
Lactitol Approved, Investigational Phase 2 585-88-6, 585-86-4 493591
25
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
26
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
27
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
29
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
30 Tanezumab Investigational Phase 2 880266-57-9
31 Angiogenesis Inhibitors Phase 2
32 Antineoplastic Agents, Immunological Phase 2
33 diuretics Phase 2
34 Endostatins Phase 2 71581480
35 Imatinib Mesylate Phase 2 220127-57-1 123596
36 Analgesics, Non-Narcotic Phase 2
37 Fibrinolytic Agents Phase 2
38 Antipyretics Phase 2
39 Platelet Aggregation Inhibitors Phase 2
40 Cyclooxygenase Inhibitors Phase 2
41 Antirheumatic Agents Phase 2
42 Anti-Inflammatory Agents, Non-Steroidal Phase 2
43 Pharmaceutical Solutions Phase 2
44 Analgesics Phase 2
45 Protein Kinase Inhibitors Phase 2
46 Immunoglobulins Phase 2
47 Antibodies Phase 2
48 Mitogens Phase 2
49 Immunologic Factors Phase 2
50 Immunoglobulins, Intravenous Phase 2

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function Suspended NCT02415257 Phase 4 Gentamicin
2 Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function Suspended NCT02379754 Phase 4 Gentamicins
3 Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery Completed NCT00438087 Phase 3 methylprednisolone
5 Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
6 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) Unknown status NCT02819479 Phase 2 25% Mannitol;Low-dose Intra-arterial Bevacizumab
7 Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping Completed NCT02104323 Phase 2 Endostatin
8 Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma Completed NCT01207687 Phase 2
9 Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors Completed NCT00973739 Phase 2 Lapatinib
10 A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Completed NCT01490476 Phase 2 RAD001
11 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
12 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
13 Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas Recruiting NCT03079999 Phase 2 Aspirin;Placebo
14 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
15 Immunotherapy Targeting Neurofibromatosis or Schwannomatosis Recruiting NCT04085159 Phase 1, Phase 2
16 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
17 Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer? Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
18 Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS) Recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
19 A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations Recruiting NCT04094610 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
20 Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT04283669 Phase 2 Crizotinib
21 A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis Active, not recruiting NCT04163419 Phase 2 Tanezumab;Placebo
22 A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
23 Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
24 Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation Active, not recruiting NCT01767792 Phase 2 Bevacizumab
25 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
26 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Not yet recruiting NCT04351373 Phase 2 intravenous fluorescein sodium
27 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Not yet recruiting NCT04374305 Phase 2 Brigatinib
28 A Phase II Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
29 Phase II Study of Antineoplastons A19 and AS2-1 in Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
30 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
31 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
32 Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma) Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
33 Scleral Hydrops and Intralabyrinthine Schwannoma Unknown status NCT03581396
34 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
35 INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS Unknown status NCT03580850
36 Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging Unknown status NCT03097822
37 Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT01743248
38 NF2 Natural History Consortium Unknown status NCT00004483
39 Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery Unknown status NCT02275325
40 Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery Unknown status NCT03520829
41 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
42 Comparative Study Between Different Approaches to CPA -Petroclival Meningiomas Unknown status NCT03462914
43 Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses Unknown status NCT03171857
44 Application of the Simultaneous PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor From Differential Diagnosis to Prediction of Prognosis Unknown status NCT02071017
45 Taste Disorders in Middle Ear Disease and After Middle Ear Surgery Unknown status NCT01584011
46 Alternatives to The Surgical Approach for Giant Spinal Schwannomas: A Clinic Trial Completed NCT02494622
47 Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
48 Assessment of Visual Sensitivity, Psychiatric Profile and Quality of Life Following Vestibular Schwannoma Surgery in Patients Prehabituated by Chemical Vestibular Ablation Completed NCT03638310
49 Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History Completed NCT01951365
50 Vestibular Evaluation Before and After Treatment of Vestibular Schwannoma. Comparison of Gamma Knife Radiosurgery and Microsurgical Resection Completed NCT03670589

Search NIH Clinical Center for Neurilemmoma

Cochrane evidence based reviews: neurilemmoma

Genetic Tests for Neurilemmoma

Anatomical Context for Neurilemmoma

MalaCards organs/tissues related to Neurilemmoma:

40
Bone, Brain, Tongue, Spinal Cord, Breast, Colon, Thyroid

Publications for Neurilemmoma

Articles related to Neurilemmoma:

(show top 50) (show all 11670)
# Title Authors PMID Year
1
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. 6
24493721 2014
2
Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. 61 54
20195187 2010
3
Palisaded encapsulated ("solitary circumscribed") neuroma of the oral cavity: a review of 55 cases. 54 61
20237984 2010
4
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. 61 54
20178741 2010
5
Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve. 54 61
19654968 2009
6
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. 54 61
19451225 2009
7
Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene. 61 54
19691769 2009
8
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. 54 61
19409384 2009
9
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). 61 54
19509233 2009
10
Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors. 61 54
19154261 2009
11
Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. 54 61
18445079 2009
12
Expanded endoscopic endonasal resection of an olfactory schwannoma. 61 54
18831660 2008
13
Identification of direct regulatory targets of the transcription factor Sox10 based on function and conservation. 54 61
18786246 2008
14
Benign schwannoma of the liver: a case report. 54 61
18756066 2008
15
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. 61 54
18593924 2008
16
Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. 61 54
18480004 2008
17
Perirenal schwannoma: a case report. 61 54
18518995 2008
18
Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. 54 61
18240308 2008
19
Schwannoma of the lip: case report and review of the literature. 54 61
18758646 2008
20
Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. 61 54
17868749 2008
21
Genesis and biology of vestibular schwannomas. 54 61
18810196 2008
22
Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. 61 54
17620986 2007
23
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. 61 54
17304235 2007
24
Phosphorylation of the NF2 tumor suppressor in Schwann cells is mediated by Cdc42-Pak and requires paxillin binding. 54 61
17175165 2007
25
Intracranial angiosarcoma arising from a schwannoma. 61 54
16995966 2007
26
Esophageal schwannoma: report of a case. 61 54
17522770 2007
27
Differential gene expression between human schwannoma and control Schwann cells. 54 61
17083475 2006
28
Down-regulation of Sox10 with specific small interfering RNA promotes transdifferentiation of Schwannoma cells into myofibroblasts. 61 54
17177851 2006
29
Melanotic nonpsammomatous trigeminal schwannoma as the first manifestation of Carney complex: case report. 61 54
17277668 2006
30
Primary intraosseous melanotic schwannoma of the fibula associated with the Carney complex. 61 54
16930334 2006
31
A functional association between merlin and HEI10, a cell cycle regulator. 54 61
16532029 2006
32
Schwannoma of the adrenal gland: report of two cases. 61 54
16699318 2006
33
Expression of doublecortin in tumours of the central and peripheral nervous system and in human non-neuronal tissues. 61 54
16520969 2006
34
Contiguous conventional and plexiform schwannomas. Report of two cases. 54 61
16509508 2006
35
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. 54 61
16409122 2006
36
The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. 61 54
16239399 2006
37
Keratin expression in schwannoma; a study of 115 retroperitoneal and 22 peripheral schwannomas. 61 54
16357842 2006
38
Primary intratracheal neurilemmoma in children: case report and literature review. 54 61
16175598 2005
39
High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. 61 54
16078050 2005
40
Pigmented neurofibroma: review of Japanese patients with an analysis of melanogenesis demonstrating coexpression of c-met protooncogene and microphthalmia-associated transcription factor. 61 54
16112003 2005
41
Rearrangements of the intermediate filament GFAP in primary human schwannoma cells. 61 54
15837555 2005
42
Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. 54 61
16036108 2005
43
Subfrontal schwannoma. 61 54
15824881 2005
44
A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. 54 61
15930266 2005
45
Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. 61 54
15609345 2005
46
Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. 61 54
15703394 2005
47
Reduced apoptosis rates in human schwannomas. 54 61
15779232 2005
48
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 54 61
15796874 2005
49
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. 54 61
15598747 2004
50
Subfrontal schwannoma without hyposmia--case report. 54 61
15686179 2004

Variations for Neurilemmoma

ClinVar genetic disease variations for Neurilemmoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SMARCB1 NM_003073.5(SMARCB1):c.*82C>TSNV Pathogenic 239481 rs878854600 22:24176449-24176449 22:23834262-23834262

Copy number variations for Neurilemmoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 163102 22 24129150 24176704 Deletion or amplification SMARCB1 Schwannoma

Expression for Neurilemmoma

Search GEO for disease gene expression data for Neurilemmoma.

Pathways for Neurilemmoma

Pathways related to Neurilemmoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.23 S100B PRKAR1A NGFR NF2 NF1 GFAP
2 11.99 VIM RDX NF2 MUC1 MSN EZR
3 11.91 RDX NF2 MSN EZR
4
Show member pathways
11.55 RDX MSN EZR
5 11.33 PDGFRA KIT ACTC1
6 11.3 RDX MSN EZR ACTC1
7 11.16 RDX MSN EZR
8 11.11 SOX10 PRKAR1A KIT
9 11 VIM SOX10 S100B PDGFRA NES GFAP
10 10.7 VIM RDX PDGFRA MSN KIT GFAP

GO Terms for Neurilemmoma

Cellular components related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.15 S100B RDX MUC1 MSN KIT EZR
2 cytoskeleton GO:0005856 10.1 VIM RDX NF2 MSN GFAP EZR
3 cell projection GO:0042995 9.97 VIM RDX PDGFRA NGFR NF2 MSN
4 focal adhesion GO:0005925 9.91 VIM RDX MSN EZR ACTC1
5 apical plasma membrane GO:0016324 9.88 RDX MUC1 MSN EZR CD34
6 ruffle GO:0001726 9.73 S100B RDX NF2 EZR
7 apical part of cell GO:0045177 9.71 RDX NF2 MSN EZR
8 intermediate filament cytoskeleton GO:0045111 9.67 VIM NES GFAP
9 cell body GO:0044297 9.62 NF2 GFAP EZR ACTC1
10 cytoplasm GO:0005737 9.6 VIM SOX10 S100B S100A1 RDX PRKAR1A
11 cell periphery GO:0071944 9.56 RDX MSN EZR CD34
12 uropod GO:0001931 9.54 MSN EZR
13 invadopodium GO:0071437 9.52 MSN EZR
14 cell tip GO:0051286 9.46 RDX EZR
15 microvillus GO:0005902 9.46 RDX PDGFRA MSN EZR
16 filopodium GO:0030175 9.35 RDX NF2 MSN EZR ACTC1

Biological processes related to Neurilemmoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.73 PRKAR1A NF2 NF1
2 regulation of cell shape GO:0008360 9.72 S100B RDX MSN KIT EZR
3 regulation of cell size GO:0008361 9.61 RDX MSN EZR
4 cellular response to thyroid hormone stimulus GO:0097067 9.58 RDX KIT
5 establishment of endothelial barrier GO:0061028 9.58 RDX MSN EZR
6 positive regulation of phospholipase C activity GO:0010863 9.57 PDGFRA KIT
7 stem cell proliferation GO:0072089 9.55 NES CD34
8 Bergmann glial cell differentiation GO:0060020 9.54 VIM GFAP
9 positive regulation of cellular protein catabolic process GO:1903364 9.54 RDX MSN EZR
10 gland morphogenesis GO:0022612 9.52 MSN EZR
11 negative regulation of interleukin-2 secretion GO:1900041 9.51 EZR CD34
12 positive regulation of histone H4 acetylation GO:0090240 9.49 SMARCB1 MUC1
13 membrane to membrane docking GO:0022614 9.48 MSN EZR
14 intermediate filament-based process GO:0045103 9.46 VIM GFAP
15 positive regulation of early endosome to late endosome transport GO:2000643 9.43 RDX MSN EZR
16 positive regulation of protein localization to early endosome GO:1902966 9.33 RDX MSN EZR
17 positive regulation of gene expression GO:0010628 9.23 VIM SOX10 RDX MSN KIT EZR
18 regulation of organelle assembly GO:1902115 9.13 RDX MSN EZR

Molecular functions related to Neurilemmoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 VIM SOX10 SMARCB1 S100B S100A1 RDX
2 protein domain specific binding GO:0019904 9.67 VIM RDX PRKAR1A EZR
3 ATPase binding GO:0051117 9.43 S100A1 RDX EZR
4 protein kinase A catalytic subunit binding GO:0034236 9.32 PRKAR1A EZR
5 cytoskeletal protein binding GO:0008092 9.26 RDX NF2 MSN EZR
6 S100 protein binding GO:0044548 8.8 S100B S100A1 EZR

Sources for Neurilemmoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....